LncRNA FAM83A-AS1 aggravates the malignant development of esophageal cancer by binding to miR-495-3p.

OBJECTIVE It is of significance to screen out differentially expressed long non-coding RNAs (lncRNAs) that can be utilized as tumor biomarkers in esophageal cancer. This study aims to uncover the effect of lncRNA FAM83A-AS1 on regulating migratory potential in esophageal cancer and the underlying mechanism. PATIENTS AND METHODS Tumor tissues and adjacent normal ones were collected from 62 esophageal cancer patients for detecting FAM83A-AS1 levels. Correlations of FAM83A-AS1 with clinical indexes and overall survival of esophageal cancer patients were analyzed. Thereafter, regulatory effects of FAM83A-AS1 on migratory potential in OE19 and OE33 cells were examined by transwell and wound healing assay. Then, the target genes of FAM83A-AS1 were predicted and functionally analyzed, and a protein interaction network was constructed. Finally, the mechanism of FAM83A-AS1 in regulating the downstream gene miR-495-3p was analyzed through Luciferase assay and rescue experiments. RESULTS It was found that FAM83A-AS1 was upregulated in esophageal cancer tissues and cell lines. Higher rates of lymphatic and distant metastasis and worse survival were observed in esophageal cancer patients expressing higher level of FAM83A-AS1. Besides, the knockdown of FAM83A-AS1 suppressed migratory potential in OE19 cells, while the overexpression of FAM83A-AS1 yielded the opposite trend in OE33 cells. Moreover, miR-495-3p was indicated to be the target gene binding FAM83A-AS1, and it was lowly expressed in esophageal cancer and negatively regulated by FAM83A-AS1. Furthermore, the overexpression of miR-495-3p partially abolished the regulatory effect of FAM83A-AS1 on migratory potential in esophageal cancer. CONCLUSIONS FAM83A-AS1 is upregulated in esophageal cancer, and it stimulates migratory potential in esophageal cancer by negatively regulating miR-495-3p.

[1]  Xing-ming Jiang,et al.  Hypoxia and lncRNAs in gastrointestinal cancers. , 2019, Pathology, research and practice.

[2]  I. Ulitsky,et al.  Regulation of gene expression by cis-acting long non-coding RNAs , 2019, Nature Reviews Genetics.

[3]  Shiming Yang,et al.  Long non‐coding small nucleolar RNA host genes in digestive cancers , 2019, Cancer medicine.

[4]  J. Lagergren,et al.  Surgical and Surgeon-Related Factors Related to Long-Term Survival in Esophageal Cancer: A Review , 2019, Annals of Surgical Oncology.

[5]  D. Chung,et al.  Screening high‐risk populations for esophageal and gastric cancer , 2019, Journal of surgical oncology.

[6]  A. Hadjinicolaou,et al.  Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers , 2019, Medical sciences.

[7]  A. Nimmo,et al.  Identification of inflammatory mediators associated with metastasis of oral squamous cell carcinoma in experimental and clinical studies: systematic review , 2019, Clinical & Experimental Metastasis.

[8]  Xin Sun,et al.  FAM83A-AS1 promotes lung adenocarcinoma cell migration and invasion by targeting miR-150-5p and modifying MMP14 , 2019, Cell cycle.

[9]  Min Su,et al.  Involvement of noncoding RNAs in epigenetic modifications of esophageal cancer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  Xitong Dang,et al.  Potential functions of esophageal cancer-related gene-4 in the cardiovascular system , 2019, Frontiers of Medicine.

[11]  J. Gong,et al.  Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. , 2019, Translational gastroenterology and hepatology.

[12]  W. Yantasee,et al.  siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion. , 2019, Translational research : the journal of laboratory and clinical medicine.

[13]  A. Zaika,et al.  From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma. , 2019, Biochimica et biophysica acta. Reviews on cancer.

[14]  L. Qin,et al.  Long noncoding RNAs, emerging and versatile regulators of tumor-induced angiogenesis. , 2019, American journal of cancer research.

[15]  Hui Zhang,et al.  Insight into long noncoding competing endogenous RNA networks in hepatic fibrosis: The potential implications for mechanism and therapy. , 2019, Gene.

[16]  Tao Wang,et al.  Long noncoding antisense RNA FAM83A‐AS1 promotes lung cancer cell progression by increasing FAM83A , 2019, Journal of cellular biochemistry.

[17]  Sheng-Jie Yu,et al.  Esophageal cancer: Risk factors, genetic association, and treatment. , 2016, Asian journal of surgery.

[18]  N. Petrelli Gastric and Esophageal Cancer 2017. , 2017, Surgical Oncology Clinics of North America.

[19]  Y. Qiao,et al.  Esophageal cancer in high-risk areas of China: research progress and challenges. , 2017, Annals of epidemiology.

[20]  Tao Wu,et al.  LncRNAs: From Basic Research to Medical Application , 2017, International journal of biological sciences.

[21]  A. Morillon,et al.  History, Discovery, and Classification of lncRNAs. , 2017, Advances in experimental medicine and biology.

[22]  Xu Gao,et al.  Long noncoding RNA H19 indicates a poor prognosis of colorectal cancer and promotes tumor growth by recruiting and binding to eIF4A3 , 2016, Oncotarget.

[23]  María José Domper Arnal,et al.  Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. , 2015, World journal of gastroenterology.

[24]  Yingsong 櫻松 Lin 林,et al.  Epidemiology of Esophageal Cancer in Japan and China , 2013, Journal of epidemiology.

[25]  Peter D Siersema,et al.  Esophageal cancer. , 2008, Gastroenterology clinics of North America.